NasdaqGM - Delayed Quote USD

Fulcrum Therapeutics, Inc. (FULC)

Compare
3.3200 +0.0600 (+1.84%)
At close: November 5 at 4:00 PM EST
3.3100 -0.01 (-0.30%)
After hours: November 5 at 5:24 PM EST

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Alexander C. Sapir CEO, President & Director 961.26k -- 1967
Mr. Alan A. Musso C.M.A., CPA Chief Financial Officer 545.1k -- 1962
Mr. Curtis G. Oltmans J.D. Senior VP, Chief Legal Officer & Corporate Secretary 585.4k -- 1963
Mr. Mel Hayes Executive Vice President of Patient Experience 631.5k -- 1970
Dr. Bradley E. Bernstein M.D., Ph.D. Founder -- -- --
Dr. Michael R. Green Founder -- -- --
Dr. Rudolf Jaenisch M.D., Ph.D. Founder -- -- --
Dr. Tsun-Huei Lee M.D., Ph.D. Founder -- -- 1964
Dr. Danny Reinberg Founder -- -- --
Mr. Gregory Tourangeau Controller & Principal Accounting Officer -- -- --

Fulcrum Therapeutics, Inc.

26 Landsdowne Street
Cambridge, MA 02139
United States
617 651 8851 https://www.fulcrumtx.com
Sector:?
Healthcare
Industry:?
Biotechnology
Full Time Employees:?
76

Description

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Fulcrum Therapeutics, Inc.’s ISS Governance QualityScore as of November 1, 2024 is 8. The pillar scores are Audit: 4; Board: 6; Shareholder Rights: 8; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

November 5, 2024 at 1:30 PM UTC - November 13, 2024 at 1:30 PM UTC

Fulcrum Therapeutics, Inc. Earnings Date

Recent Events

October 21, 2024 at 12:00 AM UTC

SC 13G: Tender Offer/Acquisition Reports

September 24, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

September 12, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

August 22, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

July 31, 2024 at 12:00 PM UTC

Q2 2024 Earnings Call

July 31, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

June 17, 2024 at 12:00 AM UTC

8-K: Corporate Changes & Voting Matters

May 13, 2024 at 12:00 AM UTC

10-Q: Periodic Financial Reports

April 24, 2024 at 12:00 AM UTC

CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission

April 19, 2024 at 12:00 AM UTC

ARS: Annual Report to Shareholders

Related Tickers